ARTCLINE Reaches 100-Patient Milestone in Septic Shock Immune Cell Therapy Trial
核心洞察
ARTCLINE (搜索) has enrolled 100 of 142 planned patients in the ReActIF-ICE clinical study evaluating ARTICE® (搜索) extracorporeal immune cell therapy for septic shock (搜索) treatment.
The randomized, controlled multicenter study is being conducted at 20 leading intensive care centers in Germany with recruitment expected to complete by end of 2025.
The novel therapy uses purified granulocyte concentrates from healthy donors to support dysfunctional immune systems in septic shock (搜索) patients, addressing a critical unmet medical need.
ARTCLINE (搜索), a German biomedical company developing novel immune cell therapies, announced that 100 patients have been enrolled in its pivotal ReActIF-ICE clinical study (NCT05442710) evaluating the ARTICE® (搜索) extracorporeal therapy for septic shock (搜索) treatment. The milestone represents significant progress toward the study's target enrollment of 142 patients across 20 leading intensive care centers in Germany.
The ARTICE® (搜索) therapy represents a novel approach to treating septic shock (搜索) by using immune cells from healthy donors to support and regenerate the dysfunctional immune systems of critically ill patients. The treatment involves administering purified granulocyte concentrates through a directed manufacturing process under GMP guidelines.
Clinical Study Design and Endpoints
The ReActIF-ICE study is a multicenter, randomized, controlled validation study designed to assess both safety and efficacy of the ARTICE® (搜索) therapy. The primary endpoint focuses on safety and tolerability, measured by the occurrence of new serious adverse events (SAEs) up to day 28. Secondary endpoints include all-cause mortality at day 28, day 90, and until hospital discharge, as well as daily changes in SOFA (Sequential Organ Failure Assessment) scores.
Patients in the treatment group receive up to 6 ARTICE® (搜索) immune cell treatments within 9 days, in addition to standard of care, while the control group receives current standard of care alone. The study is expected to complete recruitment by the end of 2025.
Addressing Critical Medical Need
Septic shock (搜索) represents one of the most challenging conditions in intensive care medicine. According to WHO data cited in the study materials, sepsis (搜索) affects 48 million people annually, including 20 million children under 5 years of age, with approximately 20% of global deaths attributed to sepsis. The mortality rate remains alarmingly high despite continuous research and development efforts.
Dr. Jens Altrichter, Managing Director and Founder of ARTCLINE (搜索) GmbH, emphasized the therapy's potential impact: "We are convinced that ARTICE® (搜索) has the potential to significantly improve treatment outcomes for patients with septic shock (搜索) and addresses the major unmet medical need for this often-fatal condition."
The immune system (搜索) impairment plays a crucial role in sepsis (搜索) progression. While modern intensive care enables many patients to survive the initial phase of septic shock (搜索), subsequent deaths often occur due to immune dysfunction leading to secondary infections and organ failure.
Clinical Perspective and Market Preparation
Prof. Martin Sauer, M.D., Chief Physician of the Department of Intensive Care and Emergency Medicine at Magdeburg Hospital, provided clinical context for the study: "Extracorporeal immune cell therapy is proving to be a viable option in clinical practice, appears to be medically useful and potentially provides a much-needed treatment for severe cases of septic shock (搜索)."
ARTCLINE (搜索) has already secured important regulatory milestones, with GMP manufacturing authorization and CE marking obtained for all components of the ARTICE® (搜索) procedure, including donor immune cells, devices, and treatment kit. This regulatory foundation supports the company's preparation for a broad market launch planned for the second half of 2026.
Therapeutic Innovation
The ARTICE® (搜索) therapy was developed through collaboration between immunologists and dialysis specialists, utilizing allogeneic immune cells from healthy donors to temporarily support key functions of patients' dysregulated immune systems. This extracorporeal approach aims to help restore immune system (搜索) activity in critically ill patients with septic shock (搜索).
The rapid enrollment progress, with 100 patients recruited ahead of schedule, suggests strong clinical interest in this novel therapeutic approach. Dr. Altrichter noted that this rapid recruitment "is a great sign, confirming that our ARTICE® (搜索) therapy has broad interest among intensive care unit clinicians."